Seres Therapeutics, Inc. (MCRB) Analysts See $-0.73 EPS

February 20, 2018 - By Stephen Andrade

 Seres Therapeutics, Inc. (MCRB) Analysts See $ 0.73 EPS

Analysts expect Seres Therapeutics, Inc. (NASDAQ:MCRB) to report $-0.73 EPS on March, 15.They anticipate $0.10 EPS change or 15.87 % from last quarter’s $-0.63 EPS. After having $-0.17 EPS previously, Seres Therapeutics, Inc.’s analysts see 329.41 % EPS growth. The stock increased 1.95% or $0.18 during the last trading session, reaching $9.42. About 101,361 shares traded. Seres Therapeutics, Inc. (NASDAQ:MCRB) has declined 64.58% since February 20, 2017 and is downtrending. It has underperformed by 81.28% the S&P500.

Seres Therapeutics, Inc. (NASDAQ:MCRB) Ratings Coverage

Among 9 analysts covering Seres Therapeutics Inc (NASDAQ:MCRB), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Seres Therapeutics Inc had 23 analyst reports since July 21, 2015 according to SRatingsIntel. As per Friday, August 4, the company rating was maintained by H.C. Wainwright. On Wednesday, February 1 the stock rating was maintained by FBR Capital with “Outperform”. The firm earned “Buy” rating on Thursday, October 22 by Bank of America. On Tuesday, July 21 the stock rating was initiated by Leerink Swann with “Outperform”. The rating was maintained by FBR Capital with “Outperform” on Friday, August 12. The company was maintained on Tuesday, August 25 by Canaccord Genuity. Cantor Fitzgerald maintained Seres Therapeutics, Inc. (NASDAQ:MCRB) rating on Wednesday, November 8. Cantor Fitzgerald has “Buy” rating and $16.0 target. The stock of Seres Therapeutics, Inc. (NASDAQ:MCRB) has “Neutral” rating given on Tuesday, July 21 by Goldman Sachs. The company was initiated on Wednesday, March 30 by FBR Capital. As per Monday, January 25, the company rating was initiated by H.C. Wainwright.

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. The company has market cap of $381.79 million. The Company’s lead product candidate is SER-109, a bacterial spore ecology, which has completed Phase II clinical study to treat multiply recurrent Clostridium difficile infection . It currently has negative earnings. The firm also develops SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a synthetic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI.

More notable recent Seres Therapeutics, Inc. (NASDAQ:MCRB) news were published by: Businesswire.com which released: “Seres Therapeutics Announces FDA Orphan Drug Designation for SER-287 in …” on December 04, 2017, also Seekingalpha.com with their article: “Seres Therapeutics’ (MCRB) CEO Roger Pomerantz on Q3 2017 Results – Earnings …” published on November 08, 2017, Businesswire.com published: “Seres Therapeutics to Present at the 36th Annual JP Morgan Healthcare Conference” on January 04, 2018. More interesting news about Seres Therapeutics, Inc. (NASDAQ:MCRB) were released by: Businesswire.com and their article: “Seres Therapeutics, MD Anderson Cancer Center, and the Parker Institute for …” published on November 14, 2017 as well as Businesswire.com‘s news article titled: “Seres Therapeutics Reports SER-287 Phase 1b Microbiome Analyses that Provide …” with publication date: January 04, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.